Article

ASCO: Early studies show promise in treating metastatic breast cancer

Author(s):

Debu Tripathy blog image

Debu Tripathy, CURE's editor-in-chief, is in Chicago for the annual meeting of the American Society of Clinical Oncology and is reporting on the latest in metastatic breast cancer. There are several targeted drugs that are being tested in early studies that appear promising. "A new drug, known as AMG-386 or trametinib, is being tested with taxol. At early glance seems to be a very active combination," he says. "But this is really an incomplete observation. We'll need to see how long these remissions last and how they compare to other drugs."The class of drugs called CDK4/6 inhibitors are also being looked at closely by scientists. "In hormone receptor-positive cancers, these drugs have already shown pretty big improvements in disease-free outcomes and may be on the verge of approval," he says. One drug is also being tested in triple-negative breast cancer. The usefulness of PARP inhibitors is still being explored for patients with metastatic breast cancer in women with BRCA mutations. A recent study of veliparib is now reporting results that show it may have activity in patients with BRCA 1 or 2 mutation.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Image of man with text.
Image of doctor with text.
Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.
Dr. Breelyn Wilky stresses the importance of expert guidance and second opinions for patients with GIST, as treatment options continue to evolve rapidly.
Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll.
An early study of BGB-16673 for hard-to-treat leukemia found that side effects were manageable with no new safety concerns.
Image of woman with text.
Image of goy, and text.
Related Content